89bio to Present at Upcoming Investor Conference
September 28 2020 - 5:18PM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced that Rohan Palekar, the
company’s Chief Executive Officer, will present at the H.C.
Wainwright 4th Annual NASH Investor Conference on Monday, October
5, 2020 at 11:30 AM ET.
The live and archived webcast of the
presentation will be accessible from the company’s website at
https://ir.89bio.com/events-and-presentations. The replay of the
webcast will be available on the company’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases. The company’s lead product candidate,
BIO89-100, is a specifically engineered glycoPEGylated analog of
FGF21. BIO89-100 is being developed for the treatment of
nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia
(SHTG). 89bio is headquartered in San Francisco with operations in
Herzliya, Israel.
Investor Contact:Ryan MartinsChief Financial
Officerinvestors@89bio.com
Media Contact:Lori RosenLDR
Communications917-553-6808lori@ldrcommunications.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2023 to Apr 2024
